mgc pharma

25 November 2022 ASX Code: MXC LSE Code: MXC

Results of the 2022 Annual General Meeting

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to announce the results of voting on resolutions put to the Company's shareholders at its 2022 Annual General Meeting, held on 24 November 2022. This information is provided in accordance with Section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

The Company advises that all resolutions put the meeting were decided on a poll, with the results of voting detailed in the accompanying table.

--Ends--

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer **CEO & Managing Director** +61 8 6382 3390

info@mgcpharma.eu

UK Financial and Corporate Advisor Hannam & Partners Rupert Fane / Nilesh Patel +44 7810 056 104 rf@hannam.partners / nilesh@hannam.partners

UK PR Advisors

Tavistock Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk MGC Pharmaceuticals Ltd David Lim **Company Secretary** +61 8 6382 3390 info@mgcpharma.eu

UK Broker Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.



MGC Pharmaceuticals Ltd ANNUAL GENERAL MEETING Thursday, 24 November 2022 Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1. Adoption of Remuneration Report	Ordinary	304,942,266	9,827,660	7,845,668	136,249,209	320,451,602	9,827,660	136,249,209	Carried
		94.52%	3.05%	2.43%		96.95%	3.05%		
2. Re-election of director - Stephen Parker	Ordinary	449,523,692	5,316,595	7,818,978	2,000,539	464,979,648	5,316,595	2,000,539	Carried
		97.16%	1.15%	1.69%		98.85%	1.15%		
3. Re-election of director - Brett Mitchell	Ordinary	448,957,163	5,883,124	7,818,978	2,000,539	464,413,119	5,883,124	2,000,539	Carried
		97.04%	1.27%	1.69%		98.73%	1.27%		
4. Approval of 7.1A Mandate	Special	444,413,201	8,396,251	8,739,162	3,111,190	461,709,525	8,396,251	3,111,190	Carried
		96.29%	1.82%	1.89%		98.18%	1.82%		
5. Ratify Convertible Notes	Ordinary	360,644,894	15,176,188	7,818,978	81,019,744	376,100,850	15,176,188	81,019,744	Carried
		94.01%	3.96%	2.03%		96.04%	3.96%		
6. Ratify Issue of Shares	Ordinary	350,967,499	17,689,740	7,878,978	88,123,587	366,543,455	17,689,740	88,123,587	Carried
		93.21%	4.70%	2.09%		95.30%	4.70%		
7. Employee Securities Plan	Ordinary	291,948,020	15,947,534	7,818,978	148,945,272	307,403,976	15,947,534	148,945,272	Carried
		92.47%	5.05%	2.48%		94.95%	5.05%		

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.